D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...
The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing Phase 2 ADVANCED-2 trial. ADVANCED-2 ...
Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...
ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...
Live Science on MSN
Color blindness linked to lower bladder cancer survival, early study hints
People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...
People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...
Stocktwits on MSN
IBRX stock finds retail cheer after company’s immunotherapy for bladder cancer gets Saudi FDA approval
ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback